Pantoprazol Farmoz (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Farmoz, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It reduces gastric acid secretion and is used in the management of acid‑related gastrointestinal conditions in hospitalised patients. GNH USA supplies Pantoprazol Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Pantoprazol Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Pantoprazol Farmoz is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related conditions: - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors. - Prevention of stress‑related mucosal damage in critically‑ill patients: reduces incidence of gastrointestinal bleeding. - Use in combination with antibiotics for Helicobacter pylori eradication regimens: enhances ulcer healing when used as part of triple therapy.

Pantoprazol Farmoz may cause adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring during treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including rash, angio‑edema, or anaphylaxis. - Clostridioides difficile‑associated colitis: severe diarrhea with abdominal pain. - Acute interstitial nephritis: inflammation of kidney interstitium. - Hepatotoxicity: elevated liver enzymes or liver injury. - Osteoporosis‑related fractures: increased risk with long‑term use. - Electrolyte disturbances: low magnesium or potassium levels.

When using Pantoprazol Farmoz, clinicians should consider several safety measures: - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease. - Long‑term therapy: evaluate risk of bone fracture and vitamin B12 deficiency. - Concomitant medications: assess for potential drug‑drug interactions, especially with drugs requiring acidic pH for absorption. - Pregnancy and lactation: prescribe only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Pantoprazol Farmoz can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (e.g., atazanavir): markedly decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - Methotrexate: increased systemic exposure, especially at high doses. - Digoxin: possible increase in serum levels. - Oral contraceptives: reduced efficacy, advise backup contraception.